Value of insulin-like growth factor system markers in the assessment of growth hormone status.
Insulin-like growth factor-I (IGF-I) has been measured extensively in a variety of clinical settings. Total IGF-I frequently is used to assess the clinical impact of disorders of GH secretion and to monitor patients' response to therapy. It does not have sufficient precision to be used as a stand-alone test in the diagnosis of GH deficiency. Free IGF-I, IGF binding protein-3, or acid-labile subunit may provide useful information regarding GH secretion in specific conditions but are not superior to IGF-I for making the diagnosis of GH deficiency or acromegaly.
Clemmons
David R
DR
Division of Endocrinology, University of North Carolina School of Medicine, University of North Carolina, CB #7170, 8024 Burnett-Womack, Chapel Hill, NC 27599, USA. endo@med.unc.edu
D000172:Acromegaly / Q000097:blood / Q000175:diagnosis; D002352:Carrier Proteins / Q000378:metabolism; D019411:Clinical Laboratory Techniques; D004393:Dwarfism, Pituitary / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D006023:Glycoproteins / Q000378:metabolism; D013006:Growth Hormone / Q000032:analysis* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000032:analysis*; D012680:Sensitivity and Specificity; D013002:Somatomedins / Q000032:analysis* / Q000378:metabolism
D002352:Carrier Proteins; D006023:Glycoproteins; D018969:Insulin-Like Growth Factor Binding Proteins; D013002:Somatomedins; C075944:insulin-like growth factor binding protein, acid labile subunit; D013006:Growth Hormone